ExploreWatchlistsPricing
  1. JP-listed companies
  2. ReproCELL Incorporated
  3. Financials
  4. Revenue growth (%)

ReproCELL Incorporated (4978)

Market cap
¥16.2B
P/E ratio
-28.2x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Mar 31, 202522.7-227.54%
Mar 31, 2024-17.8-155.44%
Mar 31, 202332.2-56.38%
Mar 31, 202273.7+923.89%
Mar 31, 20217.2-29.62%
Mar 31, 202010.2-41.61%
Mar 31, 201917.5-166.46%
Mar 31, 2018-26.4-246.85%
Mar 31, 201718-79.62%
Mar 31, 201688.1+282.75%
Mar 31, 201523+136.49%
Mar 31, 20149.7-70.26%
Mar 31, 201332.7

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat